Risk factors
Bicara Therapeutics (BCAX) risk factors
Item 1A of every Bicara Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks9 new4 dropped18 reworded
Clinical stage biopharmaceutical company Bicara Therapeutics focuses on developing its lead product candidate ficerafusp alfa, raising capital through public and private offerings, and managing regulatory and manufacturing dependencies.
Filed Mar 30, 2026 - FY2024 10-K risk factors71 risks
Bicara Therapeutics relies heavily on the clinical and commercial success of its lead product candidate, ficerafusp alfa.
Filed Mar 27, 2025